Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
382,523,969
-
Total 13F shares
-
1,209,022,771
-
Share change
-
+72,012,849
-
Total reported value
-
$2,248,308,746
-
Put/Call ratio
-
200%
-
Price per share
-
$1.86
-
Number of holders
-
305
-
Value change
-
+$138,253,220
-
Number of buys
-
154
-
Number of sells
-
102
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q2 2023
As of 30 Jun 2023,
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) was held by
305 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,209,022,771 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, ARK Investment Management LLC, VIKING GLOBAL INVESTORS LP, VANGUARD GROUP INC, Anchorage Capital Group, L.L.C., BlackRock Inc., Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., MORGAN STANLEY, and GENERAL ATLANTIC, L.P..
This page lists
305
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.